Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 4
1996 2
1998 1
1999 1
2001 6
2002 1
2003 2
2004 2
2005 3
2006 3
2007 7
2008 6
2009 4
2010 4
2011 6
2012 3
2013 1
2014 4
2015 7
2016 2
2017 3
2018 4
2019 1
2020 5
2021 7
2022 6
2023 3
2024 1
2025 2
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP. Ruiz-Saenz A, et al. Among authors: moasser mm. Nat Cancer. 2023 Feb;4(2):240-256. doi: 10.1038/s43018-022-00508-5. Epub 2023 Feb 9. Nat Cancer. 2023. PMID: 36759733 Free PMC article.
HER-2-directed, small-molecule antagonists.
Arkin M, Moasser MM. Arkin M, et al. Among authors: moasser mm. Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Curr Opin Investig Drugs. 2008. PMID: 19037833 Free PMC article. Review.
Targeting HER2 by Combination Therapies.
Ruiz-Saenz A, Moasser MM. Ruiz-Saenz A, et al. Among authors: moasser mm. J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30. J Clin Oncol. 2018. PMID: 29381433 Free PMC article. No abstract available.
CD318 is a ligand for CD6.
Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. Enyindah-Asonye G, et al. Among authors: moasser mm. Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):E6912-E6921. doi: 10.1073/pnas.1704008114. Epub 2017 Jul 31. Proc Natl Acad Sci U S A. 2017. PMID: 28760953 Free PMC article.
Two dimensions in targeting HER2.
Moasser MM. Moasser MM. J Clin Oncol. 2014 Jul 1;32(19):2074-7. doi: 10.1200/JCO.2014.55.7652. Epub 2014 May 27. J Clin Oncol. 2014. PMID: 24868026 Free PMC article. No abstract available.
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.
Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Huppert LA, et al. Among authors: moasser m. NPJ Breast Cancer. 2025 Nov 21;11(1):130. doi: 10.1038/s41523-025-00842-8. NPJ Breast Cancer. 2025. PMID: 41271741 Free PMC article.
97 results